Connection
Thomas Flaig to Prostatic Neoplasms
This is a "connection" page, showing publications Thomas Flaig has written about Prostatic Neoplasms.
|
|
Connection Strength |
|
|
|
|
|
6.154 |
|
|
|
-
Boxley PJ, Smith DE, Gao D, Kessler ER, Echalier B, Bernard B, Ormond DR, Lam ET, Kavanagh BD, Flaig TW. Prostate Cancer Central Nervous System Metastasis in a Contemporary Cohort. Clin Genitourin Cancer. 2021 06; 19(3):217-222.e1.
Score: 0.451
-
Bernard B, Flaig TW. Point-Prostate Cancer Genomic Analysis: Routine or Research Only? Oncology (Williston Park). 2018 12 17; 32(12):607-9.
Score: 0.401
-
Flaig TW, Plets M, Hussain MHA, Agarwal N, Mitsiades N, Deshpande HA, Vaishampayan UN, Thompson IM. Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol. 2017 Nov 09; 3(11):e170231.
Score: 0.372
-
Flaig TW, Potluri RC, Ng Y, Todd MB, Mehra M, Higano CS. Disease and Treatment Characteristics of Men Diagnosed With Metastatic Hormone-Sensitive Prostate Cancer in Real Life: Analysis From a Commercial Claims Database. Clin Genitourin Cancer. 2017 04; 15(2):273-279.e1.
Score: 0.345
-
Lam ET, Flaig TW. Upfront Chemotherapy for Metastatic Prostate Cancer. Oncology (Williston Park). 2015 12; 29(12):956-62.
Score: 0.325
-
Kessler ER, Flaig TW. Optimal management of recurrent prostate cancer in older patients. Drugs Aging. 2012 Nov; 29(11):871-83.
Score: 0.262
-
Lam ET, Flaig TW. Prostate cancer: celecoxib trampled in the STAMPEDE trial. Nat Rev Urol. 2012 May 29; 9(7):358-60.
Score: 0.255
-
Crawford ED, Flaig TW. Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approaches. Oncology (Williston Park). 2012 Jan; 26(1):70-7.
Score: 0.248
-
Clemons J, Glod? LM, Gao D, Flaig TW. Low-dose diethylstilbestrol for the treatment of advanced prostate cancer. Urol Oncol. 2013 Feb; 31(2):198-204.
Score: 0.240
-
Sumey C, Flaig TW. Adjuvant medical therapy for prostate cancer. Expert Opin Pharmacother. 2011 Jan; 12(1):73-84.
Score: 0.230
-
Rove KO, Flaig TW. A renaissance in the medical treatment of advanced prostate cancer. Oncology (Williston Park). 2010 Dec; 24(14):1308-13, 1318.
Score: 0.230
-
Flaig TW, Glod? M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, Su LJ, Li Y, Harrison G, Agarwal R, Crawford ED, Lucia MS, Pollak M. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate. 2010 Jun 01; 70(8):848-55.
Score: 0.222
-
Flaig TW, Glod? LM. Management of the side effects of androgen deprivation therapy in men with prostate cancer. Expert Opin Pharmacother. 2008 Nov; 9(16):2829-41.
Score: 0.199
-
Flaig TW, Tangen CM, Hussain MH, Stadler WM, Raghavan D, Crawford ED, Glod? LM. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol. 2008 Mar 20; 26(9):1532-6.
Score: 0.191
-
Flaig TW, Su LJ, Harrison G, Agarwal R, Glod? LM. Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells. Int J Cancer. 2007 May 01; 120(9):2028-33.
Score: 0.179
-
Flaig TW, Nordeen SK, Lucia MS, Harrison GS, Glod? LM. Conference report and review: current status of biomarkers potentially associated with prostate cancer outcomes. J Urol. 2007 Apr; 177(4):1229-37.
Score: 0.178
-
Flaig T, Crawford ED, Kavanagh B, Lucia S, La Rosa F, Barqawi A, Crighton F, Glod? LM. Prostate cancer in a man with multiple previous cancers. Oncology (Williston Park). 2007 Apr; 21(5):611-4.
Score: 0.178
-
Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Crighton F, Harrison GS, Pierson AS, Agarwal R, Glod? LM. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs. 2007 Apr; 25(2):139-46.
Score: 0.173
-
Bowles DW, Flaig TW. Mitoxantrone-associated acute myelogenous leukemia in a patient with high-risk adenocarcinoma of the prostate: a case report and brief review. Cancer Invest. 2006 Aug-Sep; 24(5):517-20.
Score: 0.170
-
Flaig TW, Barqawi A, Miller G, Kane M, Zeng C, Crawford ED, Glod? LM. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer. Cancer. 2006 Jul 15; 107(2):266-74.
Score: 0.170
-
Eule CJ, Flaig TW, Wong K, Graf R, Lam ET. Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations. Prostate Cancer Prostatic Dis. 2023 03; 26(1):188-193.
Score: 0.132
-
Yu EY, Hancock ML, Aronson W, Flaig T, Belkoff L, Tutrone R, Taylor R, Hardigan PC, Getzenberg RH. Phase 2 Trial of GTx-758, an Estrogen Receptor Alpha Agonist, in Men With Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2020 12; 18(6):436-443.
Score: 0.110
-
Kessler ER, Su LJ, Gao D, Torkko KC, Wacker M, Anduha M, Chronister N, Maroni P, Crawford ED, Flaig TW, Glode LM, Lam ET. Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer. Integr Cancer Ther. 2018 12; 17(4):1103-1108.
Score: 0.099
-
Castro-Alonso FJ, Dominguez-Pineda J, Rosales-Sotomayor G, Flaig TW, Bourlon MT. Initiation of ADT in a Man With Locally Advanced Prostate Cancer and Multiple Cardiovascular Risk Factors. Oncology (Williston Park). 2018 05 15; 32(5):243-6.
Score: 0.096
-
Hussain M, Tangen CM, Thompson IM, Swanson GP, Wood DP, Sakr W, Dawson NA, Haas NB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn DI, Vogelzang NJ, Glode LM. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol. 2018 05 20; 36(15):1498-1504.
Score: 0.096
-
Amini A, Raben D, Crawford ED, Flaig TW, Kessler ER, Lam ET, Maroni P, Pugh TJ. Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database. Urol Oncol. 2017 06; 35(6):438-446.
Score: 0.088
-
Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, Mahmood U, Chen RC, Chapin BF, Kavanagh BD, Pugh TJ. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. J Clin Oncol. 2016 08 20; 34(24):2835-42.
Score: 0.084
-
Rusthoven CG, Waxweiler TV, DeWitt PE, Flaig TW, Raben D, Kavanagh BD. Gleason stratifications prognostic for survival in men receiving definitive external beam radiation therapy for localized prostate cancer. Urol Oncol. 2015 Feb; 33(2):71.e11-9.
Score: 0.074
-
Rusthoven CG, Carlson JA, Waxweiler TV, Yeh N, Raben D, Flaig TW, Kavanagh BD. The prognostic significance of Gleason scores in metastatic prostate cancer. Urol Oncol. 2014 Jul; 32(5):707-13.
Score: 0.072
-
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10; 368(2):138-48.
Score: 0.066
-
de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fl?chon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26; 364(21):1995-2005.
Score: 0.059
-
Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP, Wood DP, Sakr WA, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, Glode LM. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol. 2011 May 20; 29(15):2040-5.
Score: 0.059
-
O'Bryant CL, Flaig TW, Utz KJ. Bicalutamide-associated fulminant hepatotoxicity. Pharmacotherapy. 2008 Aug; 28(8):1071-5.
Score: 0.049
-
Kessler ER, Gao D, Flaig TW, Breaker K, Wold M, Wacker M, Lam ET. Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate. Ann Oncol. 2017 03 01; 28(3):668.
Score: 0.022
-
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fl?chon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27; 367(13):1187-97.
Score: 0.016
-
Rusthoven KE, Flaig TW, Raben D, Kavanagh BD. High incidence of lung cancer after non-muscle-invasive transitional cell carcinoma of the bladder: implications for screening trials. Clin Lung Cancer. 2008 Mar; 9(2):106-11.
Score: 0.012
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|